$GSK News
Last published 2d ago
- 2d agoNVDAYUMLLYGSK+3As Nvidia probes Jensen Huang affair, here's the board member likely to play a big roleCNBCStephen Neal is the board's lead independent director and head of corporate governance. Experts say how Nvidia handles the probe is crucial to retaining its reputation.
- 1w agoALMRGSKAlamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision MedicineGlobeNewswireFREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a strategic
- 1w agoGSKAlfasigma Announces New Linerixibat Data Across PBC and Liver Disease to be Presented at AASLD’s The Liver Meeting 2026GlobeNewswireMORRISTOWN, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Alfasigma, a global pharmaceutical company, today announced that five presentations on linerixibat in primary biliary cholangitis (PBC), including one oral
- 3w agoGSKHibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)Business WireApproval based on phase III data showing unprecedented functional cure rates compared to standard of care Six-month treatment with option of self-administration after first dose CHB affects approximately 1.7
- 3w agoGSKJemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancerBusiness WireApproval based on AZUR-1 data showing clinically significant proportion of participants with no detectable signs of cancer one year or more after treatment No disease recurrences reported among responders after
- 3w agoGSKApproval of Jemperli, Bla #761174FDA Approved DrugsApproval Date: 10/19/2026; Drug Name: Jemperli, Bla #761174; Active Ingredients: DOSTARLIMAB-GXLY; Company: Glaxosmithkline; Submission Status: Approval; Application Number: 761174
- 4w agoSQGSKNVDACerebras CEO pushes back on AI doomsday warningsTechCrunch
- 1mo agoGSKViola Davis partners with GSK to educate adults 50 and older about their shingles riskPR NewswireFor the first time, Viola Davis shares her experience with shinglesViola encourages adults 50 years and older to prioritize their health and have candid conversations about increased risks that come with agingThe
- 1mo agoNVSNVOAZN-GBGSK+3Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar dealsCNBCWestern biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
- 2mo agoAZNREGNSNYGSKAstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopesCNBCThe full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
- 3mo agoMRKGSKTrump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequencesCNBCDoctors and other experts say that splitting the measles, mumps and rubella shot has no scientific basis and is unlikely to get off the ground.
- 3mo agoGSKApproval of Brexafemme, Nda #214900 (Labeling)FDA Approved DrugsApproval Date: 07/24/2026; Drug Name: Brexafemme, Nda #214900; Active Ingredients: IBREXAFUNGERP CITRATE; Company: Glaxosmithkline; Submission Status: Approval; Submission Classification: Labeling; Application Number: 214900
- 3mo agoGSKJideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancerPR NewswireGSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor,...
- 3mo agoGSKApproval of Ojjaara, Nda #216873 (Labeling)FDA Approved DrugsApproval Date: 07/20/2026; Drug Name: Ojjaara, Nda #216873; Active Ingredients: MOMELOTINIB DIHYDROCHLORIDE; Company: Glaxosmithkline; Submission Status: Approval; Submission Classification: Labeling; Application Number: 216873
- 4mo agoGSKApproval of Zyban, Nda #020711 (Labeling)FDA Approved DrugsApproval Date: 07/13/2026; Drug Name: Zyban, Nda #020711; Active Ingredients: BUPROPION HYDROCHLORIDE; Company: Glaxosmithkline; Submission Status: Approval; Submission Classification: Labeling; Application Number: 020711
- 4mo agoONNVFMRKPFEGSK+1Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging MarketGlobeNewswireAUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Oncology research is moving through one of its most active stretches in years. DNA Damage Response ("DDR") inhibitors, a category
- 4mo agoGSKSPROUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)Business WireFirst and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 More than 3 million cases of cUTIs are treated
- 4mo agoGSKSPROUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)GlobeNewswireFirst and only oral carbapenem antibiotic approved in the USApproval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatmentiMore than 3 million cases of cUTIs are treated annually in the
- 4mo agoGSKNUVLXBIIBB+3Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBCCNBCBiopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
- 5mo agoGSKApproval of Malarone Pediatric, Nda #021078 (Labeling)FDA Approved DrugsApproval Date: 06/10/2026; Drug Name: Malarone Pediatric, Nda #021078; Active Ingredients: ATOVAQUONE; PROGUANIL HYDROCHLORIDE; Company: Glaxosmithkline; Submission Status: Approval; Submission Classification: Labeling; Application Number: 021078
- 5mo agoGSKApproval of Malarone, Nda #021078 (Labeling)FDA Approved DrugsApproval Date: 06/10/2026; Drug Name: Malarone, Nda #021078; Active Ingredients: ATOVAQUONE; PROGUANIL HYDROCHLORIDE; Company: Glaxosmithkline; Submission Status: Approval; Submission Classification: Labeling; Application Number: 021078
- 5mo agoGSKNUVLPFECancer's Toughest Targets Are Drawing Wall Street's Attention as Oncology Innovation AcceleratesGlobeNewswireDENVER, June 09, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the
- 5mo agoGSKNUVLGSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FTCNBCThe deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
- 5mo agoXBIGSKLLY‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-CovidCNBCDriven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
- 5mo agoLLYGSKHealthy Returns: Eli Lilly makes a new push into vaccines – here’s what to knowCNBCThe drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.
- 5mo agoGTBPSMMTIDYAGSK+1B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters ClinicPR NewswireUSA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody could ...
- 6mo agoGSKJulie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adultsBusiness WireOn-screen parenting duo stars in new, original video highlighting relatable parenting moments, educating viewers about meningococcal disease, also known as meningitis GSK's Ask2BSure campaign encourages parents of
- 7mo agoGSKApproval of Zejula, Nda #214876 (Labeling)FDA Approved DrugsApproval Date: 03/27/2026; Drug Name: Zejula, Nda #214876; Active Ingredients: NIRAPARIB TOSYLATE; Company: Glaxosmithkline; Submission Status: Approval; Submission Classification: Labeling; Application Number: 214876
- 7mo agoPFEGSKPfizer to seek FDA approval for Lyme disease vaccine candidate despite trial missCNBCLyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.
- 8mo agoGSKGSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased RiskBusiness WireIn the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection1* GSK plc (LSE/NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has expanded the
- 8mo agoMAORCLGSKSYF+3Myriad Venture Partners Expands Executive Advisory Board as Enterprise AI Moves Into ProductionPR NewswireMyriad Venture Partners ("Myriad"), an early-stage venture capital firm focused on defining the future of business solutions in enterprise AI,...
- 8mo agoGSKApproval of Wellcovorin, Nda #018342 (Efficacy)FDA Approved DrugsApproval Date: 03/09/2026; Drug Name: Wellcovorin, Nda #018342; Active Ingredients: LEUCOVORIN CALCIUM; Company: Glaxosmithkline; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 018342
- 8mo agoBORAYGSKBora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing ContractBusiness WireBora manufactures more than 20 commercial products for GSK at its Mississauga facility, supporting infectious disease, mental health, dermatology, & other critical therapeutic areas Bora Pharmaceuticals Co., Ltd.
- 8mo agoGSKGSK's AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study ShowsBusiness WireReduction observed in RSV-related hospitalizations in adults aged ≥60 years1 An observed reduction in major adverse cardiovascular events* in adults aged ≥60 yearsǂ2 during RSV-related hospitalization Risk
- 9mo agoGILDLLYGSKABBV+6Healthy Returns: Botox, Trulicity among 15 drugs added to Medicare price negotiationsCNBCThe Trump administration kicked off another round of Medicare drug price negotiations, while Kaiser Permanente agrees to pay a historic settlement.
- 9mo agoGSKRAPTForbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSKGlobeNewswireNAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE:GSK) has entered into a definitive agreement
- 10mo agoGSKSamsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSKPR NewswireSamsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that its wholly owned U.S....
- 10mo agoGSKMRKBMYAMGN+7Nine of the largest pharma companies ink deals with Trump to lower drug pricesCNBCPresident Donald Trump has pushed to lower drug prices for Americans, which are on average nearly three times higher than overseas.
- 11mo agoGSKExdensur (depemokimab) approved by US FDA for the treatment of severe asthmaBusiness WireExdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype Approval based on SWIFT trials showing significantly lower
- 11mo agoGSKApproval of Blujepa, Nda #218230 (Efficacy)FDA Approved DrugsApproval Date: 12/11/2025; Drug Name: Blujepa, Nda #218230; Active Ingredients: GEPOTIDACIN MESYLATE; Company: Glaxosmithkline; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 218230
- 11mo agoGSKApproval of Imitrex, Nda #020626 (Labeling)FDA Approved DrugsApproval Date: 12/09/2025; Drug Name: Imitrex, Nda #020626; Active Ingredients: SUMATRIPTAN; Company: Glaxosmithkline; Submission Status: Approval; Submission Classification: Labeling; Application Number: 020626
- 11mo agoGSKApproval of Imitrex Statdose, Nda #020080 (Labeling)FDA Approved DrugsApproval Date: 12/09/2025; Drug Name: Imitrex Statdose, Nda #020080; Active Ingredients: SUMATRIPTAN SUCCINATE; Company: Glaxosmithkline; Submission Status: Approval; Submission Classification: Labeling; Application Number: 020080
- 11mo agoGSKApproval of Imitrex, Nda #020132 (Labeling)FDA Approved DrugsApproval Date: 12/09/2025; Drug Name: Imitrex, Nda #020132; Active Ingredients: SUMATRIPTAN SUCCINATE; Company: Glaxosmithkline; Submission Status: Approval; Submission Classification: Labeling; Application Number: 020132
- 11mo agoGSKApproval of Imitrex, Nda #020080 (Labeling)FDA Approved DrugsApproval Date: 12/09/2025; Drug Name: Imitrex, Nda #020080; Active Ingredients: SUMATRIPTAN SUCCINATE; Company: Glaxosmithkline; Submission Status: Approval; Submission Classification: Labeling; Application Number: 020080
- 11mo agoMRKGSKRFK Jr.’s vaccine panel weakens recommendation on hepatitis B shot for babies, scrapping universal guidanceCNBCSome public health experts expressed concerns the recommendation could lead to an increase in hepatitis B infections in babies.
- 1y agoGSKApproval of Valtrex, Nda #020487 (Labeling)FDA Approved DrugsApproval Date: 11/12/2025; Drug Name: Valtrex, Nda #020487; Active Ingredients: VALACYCLOVIR HYDROCHLORIDE; Company: Glaxosmithkline; Submission Status: Approval; Submission Classification: Labeling; Application Number: 020487
- 1y agoGSKApproval of Wellbutrin, Nda #018644 (Labeling)FDA Approved DrugsApproval Date: 11/05/2025; Drug Name: Wellbutrin, Nda #018644; Active Ingredients: BUPROPION HYDROCHLORIDE; Company: Glaxosmithkline; Submission Status: Approval; Submission Classification: Labeling; Application Number: 018644
- 1y agoGSKApproval of Wellbutrin Sr, Nda #020358 (Labeling)FDA Approved DrugsApproval Date: 11/05/2025; Drug Name: Wellbutrin Sr, Nda #020358; Active Ingredients: BUPROPION HYDROCHLORIDE; Company: Glaxosmithkline; Submission Status: Approval; Submission Classification: Labeling; Application Number: 020358
- 1y agoGSKBlenrep approved by US FDA for use in treatment of relapsed/refractory multiple myelomaBusiness WireSignificant unmet need for patients requires new and novel treatments1 DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population versus a
- 1y agoGSKSPROPIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)GlobeNewswireData presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment1Data will be shared with regulatory